MDS patients petition new UK government for access to Celgene's Vidaza
This article was originally published in Scrip
Executive Summary
Patient groups yesterday presented the UK's new Prime Minister David Cameron with a petition calling for access to Celgene's anticancer, Vidaza (5-azacitidine) to treat bone marrow diseases. The move comes after English and Scottish health technology appraisal bodies declined to recommend the drug earlier this year.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.